TuHURA Reports Q2 Cash of $1.0M, Files IND for AML Drug, Maps 2H Milestones
HURA has more than doubled off its 52-week low of $0.41.
Summary
TuHURA reported Q2 2026 results with cash of just $1.0 million at June 30, though subsequent draws on its $50 million credit facility and ATM sales have added liquidity. R&D spending rose to $6.6 million from $4.9 million a year earlier, reflecting increased clinical activity. The company filed an IND for TBS-2025 in AML and expects FDA safe-to-proceed feedback in 2H 2026, with Phase 1b/2 initiation planned. Orphan drug designations for IFx-2.0 in MCC and TBS-2025 in AML are also anticipated in 2H 2026. The low cash balance is offset by the credit facility from its largest shareholder, which management says provides runway into 2028. Additionally, TuHURA expects to initiate a Phase 1b/2 trial of VISTA in mutNPM1 R/r AML in 2H 2026.
At the time of this announcement, HURA was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.5M. The 52-week trading range was $0.41 to $3.43. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.